Search Results

Your search for Matthew Stenger matches 152 pages

Showing 151 - 152

By Matthew Stenger / Wednesday, January 10, 2018 2:51 PM

Durable Complete Responses After Discontinuation of Immunotherapy in Metastatic Melanoma

As reported in the Journal of Clinical Oncology by Robert and colleagues, a high proportion of patients with metastatic melanoma achieving complete response on pembrolizumab (Keytruda) in the phase Ib KEYNOTE-001 trial maintained complete response for prolonged durations after treatment...

bladder cancer

immunotherapy

By Matthew Stenger / Friday, January 5, 2018 3:32 PM

IMvigor211 Trial: Atezolizumab vs Chemotherapy in Platinum-Treated Advanced Urothelial Carcinoma

The phase III IMvigor211 trial showed no survival benefit for atezolizumab (Tecentriq) vs physician's choice of chemotherapy in platinum-treated locally advanced or metastatic urothelial carcinoma with programmed death-ligand 1 (PD-L1) expression ≥ 5%. Findings were reported in The Lancet by...

Apr

Today In Oncology

Search Results

Your search for Matthew Stenger matches 152 pages

Durable Complete Responses After Discontinuation of Immunotherapy in Metastatic Melanoma

IMvigor211 Trial: Atezolizumab vs Chemotherapy in Platinum-Treated Advanced Urothelial Carcinoma

Induction and Concurrent Vismodegib With Radiation Therapy for Locally Advanced Unresectable Basal Cell Carcinoma

FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non–Muscle Invasive Bladder Cancer

Predicting Ovarian Cancer Relapse With Spatial Tissue Analysis

Chemohormonal Therapy for Locally Advanced Prostate Cancer

Nivolumab With or Without Ipilimumab in Recurrent or Metastatic Cervical Cancer